Clinical Trials | December 30, 2025
One jab, six months: Leuprolide mesylate shows strong efficacy in children with precocious puberty
The study met its primary endpoint with flying colors
The study met its primary endpoint with flying colors
The partnership also sets the stage for broader collaboration on rare disease treatments
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals
Intas becomes the first and only company in India to offer IVF and gynecology therapies with needle-free injections
Tolebrutinib had been provisionally approved in the United Arab Emirates in July 2025 for nrSPMS to slow disability accumulation independent of relapse activity
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
The SAPIEN M3 transcatheter mitral valve replacement (TMVR) system is designed for patients with symptomatic moderate-to-severe or severe MR
The move strengthens Sanofi’s presence in adult immunization by combining Dynavax’s innovative vaccines with Sanofi’s global scale and development capabilities
Under the terms of the deal, AstraZeneca gains exclusive rights to JAB-23E73 outside of mainland China
Subscribe To Our Newsletter & Stay Updated
